Indiana wins $6.25M settlement from pharma firms over EpiPen prices

INDIANAPOLIS (WISH) — Indiana will receive $6.25 million as part of a settlement with pharmaceutical companies following allegations they conspired to inflate EpiPen prices by more than 600%.

Attorney General Todd Rokita announced the settlement Tuesday after filing an antitrust lawsuit against Viatris Inc., Pfizer Inc. and their subsidiaries.

The lawsuit, filed in January 2025, alleged the companies worked to maximize profits from the prescription devices while preventing competing products from entering the market. EpiPens are used to inject adrenaline into patients experiencing severe allergic reactions.

Viatris Inc. was formed in 2020 through a merger between Mylan and Upjohn, which was a subsidiary of Pfizer Inc. The legal complaint alleged these companies violated the Indiana Deceptive Consumer Sales Act, the Indiana Antitrust Act and the Medicaid False Claims Act by continually increasing prices.

According to the lawsuit, the companies maintained high prices by providing payments to pharmacy benefit managers to exclude competition. The legal action also asserted that pharmaceutical companies paid doctors to endorse the medical necessity of EpiPen two-packs, which allowed the manufacturers to stop selling individual devices.

As part of the settlement agreement, the involved pharmaceutical companies denied any wrongdoing.

This story was formatted for WIS...